Johnson & Johnson on Wednesday forecast 2026 gross sales and revenue forward of Wall Street estimates, even when together with a success of “hundreds of millions of dollars” from the drug pricing deal it signed with the Trump administration earlier this month.
J&J is considered one of 16 huge pharmaceutical corporations which have reached agreements to decrease US drug costs in trade for exemptions from Trump-imposed tariffs.
“We can’t disclose specific details, but it’s hundreds of millions of dollars,” Chief Financial Officer Joseph Wolk stated in an interview. “It’s a credit to the team here that we were able to surpass what (analyst) expectations are for 2026 by a pretty sizeable amount while digesting that impact.”
The firm forecast 2026 operational gross sales of $99.5 billion to $100.5 billion, exceeding analysts’ estimates of $98.9 billion, in line with LSEG information.
J&J expects full-year 2026 revenue coming in at $11.43 to $11.63 per share. Analysts have forecast earnings of $11.45 per share.
Despite the upbeat forecast, shares of the corporate fell 2.7 p.c in premarket buying and selling. They gained roughly 43 p.c in 2025.
The outcomes land a day after a court-appointed particular grasp really helpful that professional testimony linking the corporate’s talc merchandise to ovarian most cancers be allowed in court docket.
J&J has been combating claims over its talc merchandise in each federal and state court docket for years, and has stated its merchandise are secure and don’t trigger most cancers.
J&J additionally reported fourth-quarter 2025 revenue forward of expectations, buoyed by robust gross sales of blood most cancers remedy Darzalex, strong development in psoriasis drug Tremfya and resilience in its medical gadgets enterprise.
The upbeat efficiency comes as the corporate faces a number of challenges, together with tariff uncertainty on its medical gadgets unit and rising competitors for its blockbuster psoriasis drug Stelara from biosimilars. Stelara gross sales declined greater than analysts had forecast.
“How nice is it that Stelara was down so much – maybe even more than analysts thought – and we still continue to grow?” Wolk stated.
“If you just take Stelara out of that mix, that portfolio is growing 14 percent, 15 percent. Those are the products that we’re going to rely on for the next couple years and the balance of this decade.”
On an adjusted foundation, the healthcare conglomerate earned $6 billion, or $2.46 per share, for the quarter. Analysts had been anticipating a revenue of $2.44 per share.
Quarterly income of $24.56 billion additionally topped Wall Street expectations of $24.16 billion.
Sales in the Innovative Medicine division, its largest, grew 10 p.c to $15.76 billion within the quarter, beating estimates of $15.37 billion.
Quarterly gross sales for the gadgets enterprise rose 7.5 p.c to $8.8 billion.
By Michael Erman
Learn extra:
HED of article goes right here (in daring and linked)
DEK of article you’re including as Further Reading